EMEA Recommends Additional Studies for High-Risk Drugs

Drug Industry Daily
KEYWORDS International / risk
A A

Sponsors wishing to test new high-risk drugs for the first time in human subjects are advised to conduct additional preliminary studies in some circumstances under a new draft guideline from the European Medicines Agency (EMEA).

To View This Article:

Login

Subscribe To Drug Industry Daily